Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034085 · ClinicalTrials.gov registry record
Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 62
- Enrollment target
NCT01034085 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 62 participants.
The verdict
NCT01034085 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
Background: * Some people with schizophrenia have problems with their working memory and paying attention for extended periods. These difficulties cannot be treated with antipsychotic medications or with many standard therapies. * The prevalence of cigarette smoking among individuals with schizophrenia is about three times higher than in the general population. Research has shown that nicotine, the addictive component found in cigarettes, can help improve attentional and working memory performance. Researchers are interested in learning more about whether there may be an overlap in the cognitive functions beneficially affected by nicotine and areas of dysfunction in individuals with schizophrenia. Objectives: * To evaluate the potential of transdermal nicotine to alleviate cognitive deficits in schizophrenia, and to determine whether naturally maintained cigarette-smoking, in comparison, is an effective self-medication. * To gather preliminary data on genetics that may account for individual and group differences in the performance effects of nicotine. Eligibility: \- Current smokers (25 or more cigarettes per week for at least 1 year) between 18 and 55 years of age who are either healthy volunteers or have been diagnosed with schizophrenia/schizoaffective disorder. Design: * The study will require five visits to the research center, with an initial screening visit, a training session, and three test sessions. Ideally, all visits will occur 1 week apart. * Training session: Participants will receive training on the types of computerized cognitive and attentional behavior tests that will be given during the active portion of the study. Participants will also fill out questionnaires on nicotine use and other alcohol and drug use. * Test sessions: Participants will be assigned to random groups and will complete tests that assess cognitive performance (a) while maintaining their usual smoking behavior, (b) after minimal deprivation (3.5 hours without smoking) whi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2013-06-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01034085
The ClinicalTrials.gov registry entry for NCT01034085 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01034085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01034085 about?
NCT01034085 is a clinical study titled "Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia". Background: * Some people with schizophrenia have problems with their working memory and paying attention for extended periods. These difficulties cannot be treated with antipsychotic medications or with many standard therapies. * The prevalence of cigarette smoking among individuals with schizophr...
What is the current status of trial NCT01034085?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2009-06-02. Estimated completion is 2013-06-11.
Who is sponsoring clinical trial NCT01034085?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.